Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECTOR2 penicillin allergy oral challenge trial
ACTRN12624001107516Phase 3Recruiting
- Sponsor
- Austin Health
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in penicillin allergy and drug allergy comparing Prolonged amoxicillin challenge with Placebo control challenge (2 arms). Primary endpoint: Positive oral challenge within 7 days post first test dose. Started Mar 2025; status: recruiting.
02
Drugs
amoxicillin
03
Conditions
penicillin allergydrug allergy
Beyond the preview
Go deeper on ACTRN12624001107516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001107516.